Ranked #1 in Bengaluru by Outlook - Best Oncology Hospital
Know More
Human Papillomavirus (HPV) is one of the most common viral infections affecting the health of both men and women health. In India, HPV is a major public health concern because of its strong link to cervical cancer, which remains one of the leading causes of cancer-related deaths among women. The introduction and growing availability of the HPV vaccine in India has opened a critical pathway for prevention, yet widespread adoption remains uneven.
Understanding public acceptance, existing barriers, and the future roadmap for HPV vaccination is essential to reducing the long-term burden of HPV-related diseases in the country.
HPV is a group of more than 100 related viruses, some of which are classified as high-risk due to their association with cancers of the cervix, throat, anus, penis, vulva, and vagina. Persistent infection with high-risk HPV types—particularly HPV 16 and 18—accounts for nearly 70% of cervical cancer cases worldwide.
Key fact:
India contributes to nearly one-fifth of the global cervical cancer burden, with over 120,000 new cases reported annually. This makes prevention through vaccination a public health priority. The HPV vaccine India program aims to protect individuals before exposure to the virus, offering long-term protection and significantly lowering cancer risk.
India currently has access to multiple HPV vaccines, including both quadrivalent and nonavalent options that protect against several high-risk and low-risk HPV types. In recent years, the development of an indigenous HPV vaccine has improved accessibility and affordability.
Who should get vaccinated?
The vaccine is most effective when administered before the onset of sexual activity, which is why early immunization is strongly recommended.
HPV Vaccine Dosing Schedule:
Available Vaccines in India:
Acceptance of the HPV vaccine in India has improved gradually, particularly in urban areas and among educated populations. Increased awareness campaigns, school-based vaccination programs, and endorsements from healthcare professionals have played a positive role.
Factors contributing to growing acceptance include:
Despite these gains, overall vaccination coverage remains lower than required for population-level protection.
Several challenges continue to limit the widespread uptake of HPV vaccination across the country.
Many parents and adolescents are unaware of HPV, its link to cancer, or the existence of a preventive vaccine. HPV is often misunderstood as a rare or lifestyle-related infection rather than a common virus.
Discussions around HPV are sometimes avoided due to its association with sexual transmission. This stigma can prevent open conversations, particularly in conservative communities.
Although vaccine prices have reduced, affordability remains a concern in low-income and rural populations. Limited access to healthcare facilities further restricts vaccine reach.
Myths regarding vaccine safety, fertility issues, or long-term side effects continue to circulate, despite strong global evidence confirming vaccine safety. For a detailed discussion, see our dedicated article: Myths and facts about HPV and Cervical cancer.
Fact:
The HPV vaccine has been administered to over 100 million people worldwide and has a strong safety record, with only mild and temporary side effects reported in most cases.
The inclusion of HPV vaccination in national or state immunisation programs can significantly improve uptake. Some Indian states have already initiated school-based HPV vaccination drives, showing promising results.
Key public health strategies include:
A coordinated national approach can help normalise HPV vaccination and overcome existing barriers.
The future of HPV vaccine India initiatives looks promising, driven by policy support, domestic vaccine production, and increasing public awareness.
Nationwide inclusion in immunisation schedules could make HPV vaccination free or low-cost for eligible age groups.
Clear, culturally sensitive messaging focused on cancer prevention rather than sexual transmission can improve acceptance.
Encouraging vaccination for boys as well as girls can reduce virus circulation and protect against HPV-related cancers in men.
Combining vaccination with regular cervical cancer screening will maximise long-term public health benefits.
HPV vaccination offers long-lasting protection and has been shown to reduce HPV infections, precancerous lesions, and cervical cancer rates in countries with high coverage.
Key takeaway:
Vaccination today prevents cancer tomorrow.
The HPV vaccine in India represents a powerful tool in the fight against cervical and other HPV-related cancers. While acceptance is growing, overcoming barriers such as awareness gaps, stigma, and access challenges remains essential.With strong government support, healthcare advocacy, and community education, HPV vaccination can become a routine and widely accepted preventive measure—saving thousands of lives in the years to come. Visiting the Best Gynaecology Hospital ensures professional guidance, proper vaccination, and ongoing monitoring for women’s health.
